Equivalence of Boosted Atazanavir Based Regimens and Currently Effective HAART Regimens

Exclusion Criteria

• •Patients with underlying hepatitis B or C viral infections
• •Previously demonstrated clinically significant hypersensitivity (eg, Stevens-Johnson syndrome, erythema multiforme, or toxic skin eruptions) to any of the components of Reyataz® (atazanavir).
• •Taking other medications that are highly dependent on CYP3A or UGT1A1 for clearance
• •* Ergot medicines: dihydroergotamine, ergonovine, ergotamine, and methylergonovine such as Cafergot®, Migranal®, D.H.E. 45®, ergotrate maleate, Methergine®, and others (used for migraine headaches).
• •* Orap® (pimozide, used for Tourette's disorder).
• •* Propulsid® (cisapride, used for certain stomach problems).
• •* Triazolam, also known as Halcion® (used for insomnia).
• •* Midazolam, also known as Versed® (used for sedation), when taken by mouth.
• •* Camptosar® (irinotecan, used for cancer).
• •* Crixivan® (indinavir, used for HIV infection).
• •* Cholesterol-lowering medicines Mevacor® (lovastatin) or Zocor® (simvastatin).
• •* Rifampin (also known as Rimactane®, Rifadin®, Rifater®, or Rifamate®).
• •* St. John's wort (Hypericum perforatum), an herbal product sold as a dietary supplement,
• •* Viramune® (nevirapine, used for HIV infection).
• •* Vfend® (voriconazole).
• •Patients with grade 3 or higher elevations in transaminases (\> 10 X ULN)
• •Women of Childbearing Potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period.
• •Women who are pregnant or breastfeeding.
• •Women with a positive pregnancy test.